Related Experiment Videos
[Silent myocardial ischemia and nitrates]
1Service de Cardiologie, Hospital Ramón y Cajal, Madrid, Espagne.
Annales De Cardiologie Et D'Angeiologie
|July 1, 1997
Summary
Silent ischaemia (SI) is a serious cardiovascular risk factor in coronary heart disease. While anti-ischaemic drugs like nitrates can reduce SI events, their impact on overall mortality requires further study.
Area of Science:
- Cardiology
- Ischaemic Heart Disease
- Clinical Pharmacology
Context:
- Silent ischaemia (SI) is a common, asymptomatic finding in coronary heart disease (CHD) patients.
- SI is an independent cardiovascular risk factor, linked to myocardial oxygen imbalance.
- Its presence is noted before and after myocardial infarction, revascularization, or angioplasty.
Purpose:
- To assess the impact of anti-ischaemic treatments on cardiovascular prognosis in patients with SI.
- To determine if reducing SI events with drugs correlates with decreased morbidity and mortality.
- To evaluate the efficacy of various diagnostic tools and therapeutic strategies for SI.
Summary:
- SI results from myocardial oxygen supply-demand imbalance due to coronary atherosclerosis or spasm.
- Available anti-ischaemic drugs (nitrates, beta-blockers, calcium channel blockers) reduce the ischaemic burden and SI events.
- Diagnostic methods include stress ECG, Holter monitoring, and myocardial scans; revascularization is considered for refractory cases.
Impact:
- Anti-ischaemic drugs, particularly nitrates, show promise in reducing SI episodes and improving clinical outcomes.
- Further large-scale studies are needed to confirm if SI reduction translates to decreased overall cardiovascular mortality.
- Understanding SI's complex pathophysiology guides personalized anti-ischaemic drug selection and management.